Literature DB >> 18089735

Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types.

Raeda Z Rizk1, Neil D Christensen2, Kristina M Michael1, Martin Müller1, Peter Sehr1, Tim Waterboer1, Michael Pawlita1.   

Abstract

Most anti-human papillomavirus (HPV) capsid antibody assays are based on virus-like particles (VLP). We evaluated glutathione S-transferase (GST)-L1 fusion proteins as ELISA antigens for determining type specificity and cross-reactivity of 92 VLP-specific monoclonal antibodies (mAb) generated against nine mucosal alpha papillomavirus types of species 7, 9 and 10. The antibody panel included 25 new mAb, and 24 previously published mAb are further characterized. We determined the cross-reactivity patterns with 15 different HPV types representing 6 species (alpha1, 2, 4, 7, 9 and 10) and neutralization and cross-neutralization properties with HPV types 6, 11, 16, 18 and 45. Eighty-nine (97 %) of the antibodies including 34, 71 and 14 recognizing neutralizing, conformational and linear epitopes, respectively, reacted with the GST-L1 protein of the HPV type used as immunogen, with log titres ranging from 2.0 to 7.3. Of these 89 antibodies, 52 % were monotypic, 20 % showed intra-species and 28 % inter-species cross-reactivity. Log neutralization titres to the immunogen HPV ranged from 1.7 to 5.6. A single cross-neutralizing mAb (H6.L12) was found. ELISA titres were always higher than neutralization titres. All neutralizing epitopes were conformational and mostly type-specific. Our data show that bacterially expressed, affinity-purified GST-L1 fusion proteins display a broad variety of epitopes and thus are well suited for detection of HPV antibodies. Cross-reactivity is associated with linear as well as conformational epitopes. Distantly related mucosal and skin alpha papillomaviruses share some conformational epitopes and the phylogenetic L1-based species definition may not define a serological unit since no species-specific epitope was found.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18089735     DOI: 10.1099/vir.0.83145-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  33 in total

1.  Identification of neutralizing conformational epitopes on the human papillomavirus type 31 major capsid protein and functional implications.

Authors:  Maxime J J Fleury; Antoine Touzé; Marie-Christine Maurel; Thierry Moreau; Pierre Coursaget
Journal:  Protein Sci       Date:  2009-07       Impact factor: 6.725

2.  Seroprevalence of 8 oncogenic human papillomavirus genotypes and acquired immunity against reinfection.

Authors:  Lauren Wilson; Michael Pawlita; Phillip E Castle; Tim Waterboer; Vikrant Sahasrabuddhe; Patti E Gravitt; Mark Schiffman; Nicolas Wentzensen
Journal:  J Infect Dis       Date:  2014-02-25       Impact factor: 5.226

3.  Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay.

Authors:  Hilary A Robbins; Tim Waterboer; Carolina Porras; Troy J Kemp; Michael Pawlita; Ana Cecilia Rodriguez; Sholom Wacholder; Paula Gonzalez; John T Schiller; Douglas R Lowy; Mark Esser; Katie Matys; Sylviane Poncelet; Rolando Herrero; Allan Hildesheim; Ligia A Pinto; Mahboobeh Safaeian
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

4.  Expression of HPV-16 L1 capsomeres with glutathione-S-transferase as a fusion protein in tobacco plastids: an approach for a capsomere-based HPV vaccine.

Authors:  Syed Waqas Hassan; Mohammad Tahir Waheed; Martin Müller; Jihong Liu Clarke; Zabta Khan Shinwari; Andreas Günter Lössl
Journal:  Hum Vaccin Immunother       Date:  2014-11-19       Impact factor: 3.452

5.  Virus-like particles and capsomeres are potent vaccines against cutaneous alpha HPVs.

Authors:  Tilo Senger; Lysann Schädlich; Sonja Textor; Corinna Klein; Kristina M Michael; Christopher B Buck; Lutz Gissmann
Journal:  Vaccine       Date:  2009-12-08       Impact factor: 3.641

6.  Natural immune responses against eight oncogenic human papillomaviruses in the ASCUS-LSIL Triage Study.

Authors:  Lauren E Wilson; Michael Pawlita; Phillip E Castle; Tim Waterboer; Vikrant Sahasrabuddhe; Patti E Gravitt; Mark Schiffman; Nicolas Wentzensen
Journal:  Int J Cancer       Date:  2013-05-29       Impact factor: 7.396

7.  The use of human papillomavirus seroepidemiology to inform vaccine policy.

Authors:  Mark Schiffman; Mahboobeh Safaeian; Nicolas Wentzensen
Journal:  Sex Transm Dis       Date:  2009-11       Impact factor: 2.830

8.  A direct comparison of human papillomavirus type 16 L1 particles reveals a lower immunogenicity of capsomeres than viruslike particles with respect to the induced antibody response.

Authors:  Nadja Thönes; Anna Herreiner; Lysann Schädlich; Konrad Piuko; Martin Müller
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

9.  Identification of species-specific and cross-reactive epitopes in human polyomavirus capsids using monoclonal antibodies.

Authors:  Parmjeet Randhawa; Raphael Viscidi; Joseph J Carter; Denise A Galloway; Tim D Culp; Cathy Huang; Bala Ramaswami; Neil D Christensen
Journal:  J Gen Virol       Date:  2009-03       Impact factor: 3.891

10.  Guidelines of the Italian Society for Virology on HPV testing and vaccination for cervical cancer prevention.

Authors:  Luisa Barzon; Colomba Giorgi; Franco M Buonaguro; Giorgio Palù
Journal:  Infect Agent Cancer       Date:  2008-12-16       Impact factor: 2.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.